Superb presentation by Georgina Long! INTerpath-001: adding personalized mRNA vaccine intismeran to pembrolizumab reduced recurrence/death risk by 42% in resected stage IIB-IV melanoma (HR 0.58). A major step for cancer vaccines! #ESMO26@OncoAlert@myESMO#ESMO26
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!
#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.
• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)
No new safety signals observed.
@myESMO@oncoalert
The #ESMO2026 poster on our academic trial with carboplatin in mCRPC guided by RAD51-IF HRD status is now up in hall 5A. Come by and chat with @pablo_cresta@VHIO work with @Dolmos77@H12Octubre
UCLA Urology has a long history of impactful basic science discoveries, clinical innovation, practice-changing trials, FDA drug/imaging approvals, and mentorship of future leaders.
We are hiring a Vice-Chair of Research: recruit.apo.ucla.edu/JPF1131…
DM if questions/nominations
Thank you, @EAntonarakis ! Truly honored and grateful to @PCF_Science and the Milken Family Foundation. Thank you for your mentorship, alongside Justin Hwang and @DrJustinDrake , and to the patients who make this work possible. Excited for what's ahead! @UMNCancer
Pushing Terbium-161 PSMA Theranostics to 9.5 GBq - VIOLET Clinical Trial results at the #EANM26@EANM_NucMed
Terbium-161 emits beta radiation like lutetium-177, plus ultra-short range Auger and conversion electrons that may better target micrometastases. Our first-in-human VIOLET trial established safety up to 7.4 GBq (Lancet Oncology 2025).
So we asked: can we go higher? 12 men with mCRPC, 9.5 GBq, up to 6 cycles:
- Remarkably well tolerated: just 1 grade 3 toxicity (anaemia)
- PSA50 response 75%, PSA90 response 33%
- Median PSA-PFS and rPFS not reached
The answer is yes - and we’re not stopping ... Cohort C, a dose-dense cohort with shorter intervals between early cycles, is now underway.
Huge thanks to @PCF_Science Young Investigators @ButeauJames , @LouiseKostos and @AzadOncology , and to the whole @PeterMacCC@pros_tic team who made this investigator-initiated trial possible.
Grateful to @Isotopia_Global and the for their support
#TOP (Top Rated Oral Presentation)
Exciting opportunity for Urology & med onc trainees and practicing physicians👉Elevate your clinical and leadership skills at the @PCFnews Leadership Academy! 📍Santa Monica | Dec 3–5, 2026
✅ Expert faculty mentoring ✅ Formal certification
✅ Travel & hotel covered 👉Apply: bit.ly/4dyRWlv@urotoday
Not all prostate cancers follow the same molecular playbook! 🧬
🚨🚨Excited to share our new work in @CellReports, spearheaded by graduate student @RizwanKinza 👏and medical student Sai Manikonda👏, revealing distinct genomic alterations and transcriptional programs associated with SPOP-mutant prostate cancer. Another step toward more biologically informed precision oncology! @BCMFromtheLabs
Above all, grateful to the patients who generously contributed their biospecimens to advance cancer research. 💕
A heartfelt thank you to our collaborators for their hard work, support, and invaluable feedback throughout this journey. @CCoarfa@marthamims
And a special shout-out to the often-unsung heroes of science—our reviewers! Their thoughtful and constructive feedback made this a stronger manuscript. 💕
Proud of this team and grateful for the support of @BCMDeptMedicine@bcmhouston, @PCF_Science, CDMRP PCRP and @NIH@theNCI
🔗cell.com/cell-reports/fullte…
This work was funded by @fredhutch, @theNCI, @PCFnews@PCF_Science, @AmericanCancer, @CDMRP, the Larry & Virginia Gordon Endowed Chair, and the Mathews Family, Stinchcomb Family, and Thomas & Patricia Wright memorial funds.
Of note, @yeonsookim_phd (@theNCI K99/R00 awardee) is on the academic job market, so keep an eye out for her. She is an outstanding RNA and cancer biologist!
What an inspiring few days at the Prostate Cancer Foundation Annual Scientific Retreat! 🔬🌍
We were so proud to present two new CRIS Cancer–PCF Young Investigator Awards to Kirsty Hodgson (Newcastle University) and Nicolás Anselmino (VHIO). 🏆
#ProstateCancer
New in #practicalRO: Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) Trial: Protocol, Early Results, and Implications of Neoadjuvant ADT for Focal RT Boost in Prostate Cancer. This article was presented during #ASTRO2026 in Quick Pitch Session 22.